Antimicrobial resistance and eradication strategies for Helicobacter pylori

Reviews in Gastroenterological Disorders

Volumn 9, Issue 3, 2009, Pages

  Vakil, Nimish ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dyspepsia; Helicobacter pylori; Peptic ulcer disease; Quadruple therapy; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH; BISMUTH BISKALCITRATE PLUS METRONIDAZOLE PLUS TETRACYCLINE; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG; ANTACID AGENT; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

BACTERIAL STRAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LEUKOPENIA; MYALGIA; NONHUMAN; REVIEW; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; GENETICS; MUTATION;

ANTACIDS; ANTI-INFECTIVE AGENTS; BISMUTH; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MUTATION; PROTON PUMP INHIBITORS;

EID: 77649196358     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: 10.3909/rigd0352     Document Type: Review

References (30)

1. Megraud F. Helicobacter pylori and antibiotic resistance. Gut. 2007;56:1502.
2. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985-1001.
3. Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol. 2009;104:26-30.
4. Co EM, Schiller NL. Resistance mechanisms in an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother. 2006;50:4174-4176.
5. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088-1094.
6. Bruce MG, Bruden DL, McMahon BJ, et al. Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. Helicobacter. 2006;11:581-588.
7. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820-823.
8. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95:3393-3398.
9. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562-567.
10. Laine L, Suchower L, Frantz J, et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998;93:2106-2112.
11. Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med. 1998;158:1651-1656. (Pubitemid 28371188)
12. Bochenek WJ, Peters S, Fraga PD, et al; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8:626-642. (Pubitemid 37553437)
13. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107. (Pubitemid 38938723)
14. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection. J Clin Gastroenterol. 2004;38:326-331.
15. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ. 2008;336:651-654.
16. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by the Maastricht III consensus conference and a third line empirical regimen. Am J Gastroenterol. 2009;104:21-25.
17. Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346-354.
18. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology. 2002;123:1763-1769.
19. Calvet X, Ducons J, Guardiola J, et al; Group for Eradication Studies from Catalonia and Aragon. (Gresca). One-week triple vs. quadruple therapy for Helicobacter pylori infection-a randomized trial. Aliment Pharmacol Ther. 2002;16:1261-1267.
20. O'Morain C, Borody T, Farley A, et al; International multicentre study. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003;17:415-420.
21. Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-1143. (Pubitemid 36605750)
22. Jafri NS, Hornung C, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment. Ann Intern Med. 2008;148:923-931.
23. Gatta L, Di Mario F, Zullo A, Vaira D. Errors in a meta-analysis of treatments for Helicobacter pylori infection. Ann Intern Med. 2008;149:686.
24. Sánchez-Delgado J, Calvet X, Bujanda L, et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol. 2008;103:2220-2223.
25. Wu D, Hsu P, Wu J, et al. Randomized controlled comparison of sequential and quadruple therapies for H pylori infection. Gastroenterology. 2008;134(suppl):A-24.
26. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth- based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-496.
27. Di Caro S, Franceschi F, Mariani A, et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis. 2009;41:480-485
28. Gisbert JP, Bermejo F, Castro-Fernández M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103:71-76.
29. Gisbert JP, Gisbert JL, Marcos S, et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-1474.
30. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to- eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther. 2007;26:1537-1542.